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Pyoderma gangrenosum (PG) is a neutrophilic dermatosis of unknown aetiology. Clinical manifestations of PG are characterized
by destructive, necrotizing, and noninfective ulceration of the skin. 20–30% of cases are initiated and aggravated by minor
trauma or surgery, a phenomenon named pathergy. PG is related to several autoimmune diseases including ulcerative colitis,
Crohn’s disease, rheumatoid arthritis, and monoclonal gammopathy. The association with Takayasu’s arteritis (TA), a chronic
inﬂammatory and stenotic disease of large and medium-sized arteries, is instead less common. We report a case of PG associated
with TA that was induced by an accident with folgoration of the skin; in this case the folgoration can be considered as an exemple
of Pathergy, that is, a characteristic feature of PG.
Copyright © 2009 A. G. Richetta et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Pyoderma gangrenosum (PG) is a neutrophilic dermatosis
of unknown aetiology. Clinical manifestations of PG are
characterized by destructive, necrotizing, and noninfective
ulceration of the skin mostly on the lower extremities. 20–
30% of cases are initiated and aggravated by minor trauma
or surgery, a phenomenon named pathergy [1].
PG is related to several autoimmune diseases including
ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and
monoclonal gammopathy. The association with PG is also
a well-known complication of Takayasu’s arteritis (TA), a
chronic inﬂammatory, and stenotic disease of large and
medium-sized arteries [2].
Most cases of pyoderma gangrenosum associated with
Takayasu’s arteritis have been observed in Japan, while
reports appeare rarely in the Western literature [3–7].
2.CaseReport
We describe the case of a 75-year-old Caucasian woman
presented to our attention for the presence of many esulcer-
ative lesions on the legs, with unruﬄed limits and violaceus
borders.
The patient had an accident two months before with
folgoration of the skin but without any involvement of
interior organs. After the accident she was submitted to a
surgical intervention of autologous skin grafting but it was
a failure, obtaining only a partial taking root (Figure 1).
The patient referred to be aﬀected by TA, diagnosed 28
years before.
At the physical examination she presented an asymmetry
of radial arterial pulse, with diminished left arterial pulse
intensity.
As the patient presented to our attention, we ﬁrstly made
a bacterial swab of skin ulcers which responce showed an
infection with Staphylococcus aureus, while serological tests
revealed a state of inﬂammation; the patient underwent to
antibiotic therapy with Minocyclin 100mg twice a day for 10
days.
Local wound care was based on the use of collagen, silver
and nonadherent medications, but we did not obtain any
improvement of the skin lesions.
Even more during time new lesions began to appeare,
starting as pustules and gradually involving in esulcerative
lesions, characterized by a progressive external expansion,
unruﬄed limits and violaceus borders (Figure 2).
Then we decided for submitting the patient to a skin
biopsy, which histopathologic examination showed a severe2 Dermatology Research and Practice
Figure 1: Esulcerative lesions on the legs, with unruﬄed limits and
violaceus borders.
Figure 2: Pustules gradually involving in esulcerative lesions,
characterized by a progressive external expansion, unruﬄed limits
and violaceus borders.
inﬂammation with a dense neutrophilic inﬁltrate in the der-
mis. The clinical features and the histopathological ﬁndings
were consistent with a diagnosis of PG, so that we decided to
initiate a treatment with systemic prednisone 40mg once a
day and a topical corticosteroid applied once daily.
Within 2 weeks wounds showed marked signs of
improvement and systemic prednisone was gradually
reduced in a month, obtaining a complete resolution of the
skin lesions (Figure 3).
3. Discussion
PG is an uncommon ulcerative neutrophilic dermatosis with
distinctive clinical characteristics and a frequent association
with systemic disease. It is characterized by a progressive
and a recurrent skin ulceration. The lesions most commonly
occur on the legs, but they may also occur elsewhere.
The classic form of PG is characterized by a deep ulcer-
ation with a violaceous border; the skin lesions are painful,
present with undermined edges and a necrotic base, and
often go rapidly enlarging. The atypical form has a vesiculo-
pustularcomponent[1].Disordersclassicallyassociatedwith
pyoderma gangrenosum include inﬂammatory bowel dis-
ease, rheumatoid arthritis, paraproteinemia and myelopro-
liferative disorders; the association with TA is less common.
Figure 3: The complete resolution of the skin lesions after one
month of therapy.
Takayasu’s arteritis is a large vessel vasculitis char-
acterized by stenosis or occlusion of the aorta and its
branches, it usually aﬀects young women and it is com-
mon in Japan, South-east Asia, India, Middle and South
American countries. Its aetiology is unknown. Cutaneous
manifestations have been estimated to aﬀect between 2.8%
and 28% of patients, depending on race [8, 9]. They
include erythema nodosum in Europe and North America,
pyoderma gangrenosum in Japan, ulcerated nodular lesions,
erythema induratum, papulonecrotic eruptions, popular
erythematous lesions on the hands and feet, facial erup-
tions resembling lupus erythematosus, postgranulomatous
anetoderma, erythema multiforme, urticaria, cutaneous pol-
yarteritis nodosa, granulomatous vasculitis and Raynaud’s
phenomenon [3–7].
In Europe the mean age of presentation is 41 years and
women are more commonly aﬀected than men [10].
PG is a well-known complication of Takayasu’s arteritis
(TA) in Japan, while this association is very rare in North
AmericaandEurope,sothatthisconditionhasnotbeenfully
described in literature [2].
The features of PG are not speciﬁc histopathologically
andforthisreasondiagnosisisoftenbasedonclinicalfeature
[11].OurpatienthadclinicalsignsofPGthatwereconsistent
with the pustular variant of PG; our diagnosis was also
supported by the histological features of the aﬀection.
The wounds showed no signs of healing despite therapy
with systemic antibiotics and local wound care, supporting
the diagnosis of PG.
We have reported a case of PG associated with TA,
developed after an accident with folgoration of the skin. In
this case the folgoration may be considered an example of
Pathergy, that is the initiation of new lesions from sites of
previous trauma.
Pathergy is a characteristic feature of PG. It occurs in
20–30% of patients with PG and it may result from minor
trauma such as debridement, minor cutaneous surgery or
major surgery [1].Dermatology Research and Practice 3
To our knowledge this is the ﬁrst case described in
literature of folgoration as an example of induction of PG
in a patient aﬀected by TA.
We observed a rapid and complete resolution of the skin
lesions with oral corticosteroid therapy.
Corticosteroids are the treatment of choice for pyoderma
gangrenosum. In corticosteroid-resistant pyoderma gan-
grenosum, many other systemic agents such as minocycline
and methotrexate have been tried with varying success.
Intravenous immune globulin has also been used to treat
pyoderma gangrenosum, although no reports of its use
in Takayasu’s arteritis could be found. Cyclosporin has
been reported to be eﬀective in severe cases of pyoderma
gangrenosum [10].
Corticosteroids are also the treatment of choice for
patients with Takayasu’s arteritis; however, some patients
with monophasic self-limiting disease require no speciﬁc
treatment [12].
Then, ﬁrst-line therapy in disseminated PG is sys-
temic treatment with prednisone (0.5–1mg/kg/day) or
cyclosporine (5mg/kg/day) alone or combined due to their
anti-inﬂammatory and immunosuppressant properties and
rapid eﬃcacy [13]. Several studies suggests antiTNFα as a
promising alternative to the common immunosuppressive
treatment regimens [11, 14, 15].
Concluding, it is very important to meditate that when a
wound is not healing despite relevant local wound manage-
ment and systemic treatment if needed, the clinician should
always suspect PG. Early diagnosis and treatment is in fact
crucial in the management of this skin aﬀection.
It is also very important to remember the rare possibility
of underlying Takayasu’s arteritis in all patients with pyo-
derma gangrenosum.
Finally, particular attention must be reserved to trigger
factors and pathergy as cause of induction or reactivation of
PG.
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